{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:29:44Z","timestamp":1788269384965,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Borderline resectable pancreatic cancer (BRPC) poses significant surgical challenges due to tumor-vessel involvement and high risk of positive margins and early recurrence. While neoadjuvant chemoradiotherapy has demonstrated potential benefits in this setting, the role of intensity-modulated radiation therapy (IMRT) combined with gemcitabine and nab-paclitaxel has not been specifically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center retrospective cohort study, we analyzed patients with histologically confirmed borderline resectable pancreatic ductal adenocarcinoma treated between 2019 and 2022 who ultimately underwent curative-intent resection. Patients either underwent upfront surgery or received neoadjuvant chemoradiotherapy consisting of gemcitabine (1000 mg\/m\u00b2) and nab-paclitaxel (125 mg\/m\u00b2) combined with IMRT (36 Gy in 20 fractions), followed by surgery when feasible. Overall survival (OS) and recurrence-free survival (RFS) were calculated from the date of surgery. To address baseline imbalances, propensity score overlap weighting was performed to estimate the average treatment effect in the overlap population (ATO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 152 patients were included, with 109 in the upfront surgery group and 43 in the chemoradiotherapy group. In unweighted analyses, median RFS was 27 months (95% CI 20.4-33.6) in the chemoradiotherapy group versus 13 months (95% CI 8.2-17.8) in the upfront surgery group (HR 0.61, 95% CI 0.39-0.94; p=0.026), and median OS was 33 months (95% CI 19.5-46.5) versus 21 months (95% CI 14.1-28.0) (HR 0.58, 95% CI 0.36-0.94; p=0.027). In ATO-weighted analyses, median RFS was 25 months (95% CI 14-not reached) versus 11 months (95% CI 8-17) (HR 0.56, 95% CI 0.35-0.88; p=0.013), and median OS was 33 months (95% CI 19-not reached) versus 17 months (95% CI 14-24) (HR 0.56, 95% CI 0.34-0.94; p=0.027).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neoadjuvant chemoradiotherapy with IMRT plus gemcitabine and nab-paclitaxel was associated with improved surgical and survival outcomes in patients with BRPC compared to upfront surgery. These findings support the integration of modern chemoradiotherapy into the neoadjuvant treatment paradigm for BRPC and warrant prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1744117","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:22:48Z","timestamp":1770096168000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Surgical and survival outcomes of neoadjuvant IMRT-based chemoradiotherapy versus upfront surgery in borderline resectable pancreatic cancer: a retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinru","family":"Huang","sequence":"first","affiliation":[{"name":"Burn and Wound Center, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Cai","sequence":"additional","affiliation":[{"name":"Trauma and Emergency Surgery, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i31.10740","article-title":"Borderline resecta ble pancreatic cancer: definitions and management","volume":"20","author":"Lopez","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-2886-9","article-title":": Borderline resecta ble pancreatic cancer: need for standardization and methods for optimal clinical trial design","volume":"20","author":"Katz","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline resecta ble pancreatic cancer: definitions, management, and role of preoperative therapy","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0295-2","article-title":"Krishnan S et\u00a0al: Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma","volume":"16","author":"Katz","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17183085","article-title":"Neoadjuvant therapy in pancreatic ductal adenocarcinoma: aligning guideline recommendations with real-world evidence","volume":"17","author":"Cammarata","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02274","article-title":"van Dam RM et\u00a0al: Preoperative Chemoradiotherapy Versus Immediate Surgery for Resecta ble and Borderline Resect able Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Wolff RA et\u00a0al: Borderline resecta ble pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surgeons"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.11.003","article-title":"Intensity-modulated radiotherapy in treatment of pancreatic and bile duct Malignancies: toxicity and clinical outcome","volume":"59","author":"Milano","year":"2004","journal-title":"Int J Radiat oncology biology Phys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.10.043","article-title":"Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers","volume":"79","author":"Yovino","year":"2011","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Saleh MN et\u00a0al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003284","article-title":"Harmsen WS et\u00a0al: Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline\/Locally Advanced Pancreatic Cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resecta ble and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resecta ble and borderline resecta ble pancreatic cancer","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26651","article-title":"Crane C et\u00a0al: Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome","volume":"118","author":"Chatterjee","year":"2012","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resecta ble and borderline resecta ble pancreatic cancer: A meta-analysis of randomised controlled trials","volume":"160","author":"van Dam","year":"2022","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02233","article-title":"Busch OR et\u00a0al: Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resecta ble and Borderline Resecta ble Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10870","article-title":"Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resecta ble or borderline resecta ble pancreatic cancer","volume":"105","author":"Versteijne","year":"2018","journal-title":"Br J Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"zrae172","DOI":"10.1093\/bjsopen\/zrae172","article-title":"Neoadjuvant treatment versus upfront surgery in borderline resecta ble and resecta ble pancreatic ductal adenocarcinoma: meta-analysis","volume":"9","author":"Dickerson","year":"2025","journal-title":"BJS Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07309-8","article-title":"Oda Y et\u00a0al: Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resecta ble Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery","volume":"26","author":"Miyasaka","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"Kishiwada M et\u00a0al: International consensus on definition and criteria of borderline resecta ble pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology: Off J Int Assoc Pancreatology (IAP) [et al]"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx180","article-title":"Borderline resecta ble pancreatic cancer: conceptual evolution and current approach to image-based classification","volume":"28","author":"Gilbert","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1744117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:22:49Z","timestamp":1770096169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1744117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1744117"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1744117","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1744117"}}